The FDA-approved smoking cessation pill, varenicline, has emerged as a pivotal tool in addressing the escalating vaping epidemic among teens and young adults.A recent study published in JAMA highlights its effectiveness, showing that participants aged 16 to 25 who used varenicline were three times more successful at quitting vaping compared to those receiving only behavioral counseling.